Hikma Pharmaceuticals PLC (HKMPF)
OTCMKTS · Delayed Price · Currency is USD
23.98
-1.23 (-4.90%)
At close: Oct 15, 2025
Hikma Pharmaceuticals Revenue
Hikma Pharmaceuticals had revenue of $1.66 billion in the half year ending June 30, 2025, with 16.19% growth. This brings the company's revenue in the last twelve months to $3.22 billion, up 6.60% year-over-year. In the year 2024, Hikma Pharmaceuticals had annual revenue of $3.13 billion with 8.77% growth.
Revenue (ttm)
3.22B
Revenue Growth
+6.60%
P/S Ratio
1.65
Revenue / Employee
338.53K
Employees
9,500
Market Cap
5.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
| Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
| Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
| Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
| Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Hikma Pharmaceuticals News
- 19 days ago - FTSE 100 hits another high despite concerns over US government shutdown - Evening Standard
- 2 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript - Seeking Alpha
- 2 months ago - Hikma Pharmaceuticals PLC 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript - Seeking Alpha
- 2 months ago - Hikma Pharmaceuticals tumbles after injectables margin outlook cut - Reuters
- 3 months ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 3 months ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 4 months ago - Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D - Seeking Alpha